Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

800-Patient study aims to tailor sarcoma treatment

NCT ID NCT07432932

Knowledge-focused Sponsor: Royal Marsden NHS Foundation Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is collecting tissue samples and medical data from 800 high-risk sarcoma patients to develop personalized treatment approaches. Researchers will analyze genetic and protein profiles to better predict which patients benefit from chemotherapy before surgery. The goal is to create a tool that helps doctors choose the most effective treatment for each individual.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to personalized chemotherapy plans for high-risk sarcoma patients, potentially improving survival and reducing recurrence.
What could go wrong
This is an observational study, not a treatment trial. It may not directly benefit participants, and the findings might not translate into clinical practice for years.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 800 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2021

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with one of DDLPS, LMS, SS, vascular sarcomas or MPNST either advancing directly to surgery or receiving neoadjuvant chemotherapy and surgery

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent for the prospective cohort * Histopathological diagnosis of high-risk soft tissue sarcoma and one of the following subtypes: DDLPS, LMS, SS, vascular sarcomas or MPNST. Other subtypes may be included with PI approval. * High-risk sarcoma definition: * Greater than 5cm or Grade 3 * Deep anatomic location * Have disease amenable to biopsy o Patients who are not amenable to repeat biopsy at baseline can be reviewed with the local site PI for consideration of inclusion to the study * Resectable tumour * Measurable disease by RECIST 1.1 * Aged ≥ 18 years * WHO performance status 0-2 * For patients receiving NCT, medically fit enough, with adequate organ function, to undergo neoadjuvant chemotherapy * Patients medically fit enough to undergo surgical resection * Capable of giving written informed consent (for prospective cohort) and comply with the study schedule * Patients may also participate in the STRASS 2 trial Exclusion Criteria: -Prior invasive malignancy in last 5 years, low risk malignancies in the last 5 years may be reviewed by the PI. * Known additional malignancy that is progressing or requires active treatment * Metastatic disease not amenable to curative intent local therapy * Any active uncontrolled medical conditions

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Angiosarcoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

angiosarcoma childhood malignant schwannoma dedifferentiated liposarcoma leiomyosarcoma liposarcoma retroperitoneal sarcoma sarcoma soft tissue sarcoma synovial sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Angiosarcoma Leiomyosarcoma (LMS) Liposarcoma Liposarcoma, dedifferentiated Retroperitoneal sarcoma Sarcoma Sarcoma, leiomyo-, adult Sarcoma, synovial, adult Soft tissue sarcoma (STS) Soft tissue sarcoma adult Soft tissue sarcoma of the limb Soft tissue sarcoma of the trunk and extremities

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Royal Marsden Hospital

    RECRUITING

    London, SW3 6JJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.